The generated SC-β cells with ZnT8 LOF obtain improved insulin secretion capacity, resist glucotoxicity and lipotoxicity, and show significantly improved glycemic control in diabetic mice, offering an advanced strategy for stem cell-based cell replacement therapy for insulin-dependent diabetes. Here, INS is linked to type 1 diabetes mellitus.